The coronavirus disease (COVID-19) was declared a pandemic by the World Health Organization (WHO) on March 11, 2020. Facing a new and unknown virus, the entire medical community made considerable efforts to find a specific treatment, develop guidelines, and even create a vaccine. Besides all the measures taken, a wide range of complications associated with the disease increased the mortality and morbidity rates, adding more difficulty to the management of the patients. We performed a retrospective study, including the patients with SARS-CoV-2 pneumonia who were admitted to our hospital between March 2020 and August 2021. We analyzed complications that developed during the hospitalization, such as respiratory failure or acute injury to other organs (the heart, pancreas, kidneys, and liver), and whether they were treatment- and hospitalization-related. One thousand eight hundred and forty-four cases were evaluated, and we analyzed the complications that developed during the hospitalization. Out of this, 1392 (75.48%) cases developed at least one complication during hospitalization, most frequently respiratory failure (71.14%), hyperglycemia (43.54%), renal injury (42.67%), or cardiovascular events (7.10%). SARS-CoV-2 infection in hospitalized patients with pneumonia can cause injuries to any organ, making the management of those patients even more difficult.

Background/Objectives: Real-world data on pulmonary arterial hypertension (PAH) in Romania are scarce. This study evaluated the clinical characteristics, long-term survival patterns and the prognostic utility of baseline variables in a Romanian PAH cohort. Methods: We retrospectively analyzed adult patients treated for PAH at a single expert center between 2007 and 2026. The primary outcome was a composite of all-cause mortality or lung transplantation. Survival was assessed using Kaplan–Meier and univariable Cox proportional-hazard regression models. Univariable and multivariable linear regressions were used to identify drivers of baseline estimated glomerular filtration rate (eGFR). Results: The primary analysis cohort included 75 patients (mean age 53 ± 15 years, 71% female). Overall transplant-free survival was unexpectedly high at 97.2%, 80.8%, and 66.7% at 1, 3, and 5 years, respectively. The European Society of Cardiology (ESC)/European Respiratory Society (ERS) 3-strata risk score did not stratify survival (log-rank p = 0.9). Significant predictors of adverse outcomes in univariable analysis included six-minute walking distance (6MWD), PAH etiology and baseline coronary artery disease. In univariable analysis, lower baseline eGFR was associated with age, hypertension and diabetes mellitus, but not with pulmonary hemodynamics or transplant-free survival. Conclusions: In this regional PAH cohort, survival rates were high, likely reflecting survivor bias stemming from delayed access to care. Adverse outcomes were associated with PAH etiology and 6MWD, but the limited number of events precluded multivariable analysis.